Tirzepatide at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. As a "twincretin," it activates both incretin pathways simultaneously, producing synergistic effects on insulin secretion, appetite suppression, and weight loss that exceed those achievable through GLP-1 agonism alone.
FDA approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023, tirzepatide represents the next generation of metabolic pharmacotherapy. In head-to-head modeling and indirect comparisons, tirzepatide produces approximately 20-22% mean body weight loss at the highest doses - meaningfully superior to semaglutide's 15-17%.
The addition of GIP receptor agonism appears to enhance both the efficacy and tolerability of tirzepatide relative to GLP-1 agonism alone. GIP receptors are expressed in adipose tissue, where GIP signaling influences fat storage and utilization; activation of these receptors may explain part of tirzepatide's superior fat loss profile. The SURMOUNT and SURPASS trial programs provide an extensive clinical evidence base.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.